Vaccines Market: 2020 Worldwide Opportunities, Market Share, Key Players and Competitive Landscape

The global vaccines market size is expected to be USD 93.08 billion by 2026, exhibiting a CAGR of 10.7% during the forecast period. The growing prevalence of malaria around the world is a key factor boosting the vaccines market. According to the World Health Organization, in 2017, there were an estimated 219 million cases of malaria in 87 countries. Total funding for malaria control and elimination reached an estimated US$ 3.1 billion in 2017. Contributions from governments of endemic countries amounted to US$ 900 million, representing 28% of total funding. Furthermore, the increasing number of deaths caused by malaria has impelled government and pharmaceutical companies to develop advanced vaccines. According to the latest world malaria report, released in November 2018, there were 219 million cases of malaria in 2017, up from 217 million cases in 2016. The estimated number of malaria death stood at 435 000 in 2017, a similar number to the previous year.

Highlights of the Report:

• In-depth analysis of various insights, namely, Vaccines Market trends, growth drivers, opportunities, and other related challenges.
• Comprehensive details of key market players, their core competencies, and Vaccines Market share.
• The potency of suppliers and buyers to make better business decisions.
• Lists out the market size in terms of volume.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769

Key Players Operating in The Vaccines Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• GlaxoSmithKline plc.
• Sanofi
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Emergent BioSolutions, Inc.
• CSL Limited
• Inovio Pharmaceuticals, Inc.
• Bavarian Nordic
• Mitsubishi Tanabe Pharma Corporation.
• Other Prominent Players
Presence of Strong Manufacturers will Propel Growth in North America
North America generated a revenue of USD 22.03 billion in 2018 and is expected to remain dominant during the forecast period. The presence of strong manufacturers and secure government policies regarding human welfare will bolster growth in the region. Europe is expected to witness considerable growth during the forecast period. Diverse human vaccines policies across European countries such as Germany and France and robust government support will boost the vaccines market trends in Europe.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/vaccines-market-101769

Detailed Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. New Product Launch
4.2. Pipeline Analysis
4.3. Technological Advancements in the Vaccines Market
4.4. Prevalence of Disease Indications
4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
5. Global Vaccines Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Type
5.2.1. Recombinant/Conjugate/Subunit
5.2.2. Inactivated
5.2.3. Live Attenuated
5.2.4. Toxoid
5.3. Market Analysis, Insights and Forecast – By Route of Administration
5.3.1. Parenteral
5.3.2. Oral
5.4. Market Analysis, Insights and Forecast – By Disease Indication
5.4.1. Viral Diseases
5.4.2. Bacterial Diseases
5.5. Market Analysis, Insights and Forecast – By Age Group
5.5.1. Pediatric
5.5.2. Adults
5.6. Market Analysis, Insights and Forecast – By Distribution Channel
5.6.1. Hospital & Retail Pharmacies
5.6.2. Government Suppliers
5.6.3. Others
5.7. Market Analysis, Insights and Forecast – By Geography
5.7.1. North America
5.7.2. Europe
5.7.3. Asia pacific
5.7.4. Latin America
5.7.5. Middle East & Africa
6. North America Vaccines Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Type
6.2.1. Recombinant/Conjugate/Subunit
6.2.2. Inactivated
6.2.3. Live Attenuated
6.2.4. Toxoid
6.3. Market Analysis, Insights and Forecast – By Route of Administration
6.3.1. Parenteral
6.3.2. Oral
6.4. Market Analysis, Insights and Forecast – By Disease Indication
6.4.1. Viral Diseases
6.4.2. Bacterial Diseases
6.5. Market Analysis, Insights and Forecast – By Age Group
6.5.1. Pediatric
6.5.2. Adults
6.6. Market Analysis, Insights and Forecast – By Distribution Channel
6.6.1. Hospital & Retail Pharmacies
6.6.2. Government Suppliers
6.6.3. Others
6.7. Market Analysis, Insights and Forecast – By Country
6.7.1. U.S.
6.7.2. Canada
7. Europe Vaccines Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Type
7.2.1. Recombinant/Conjugate/Subunit
7.2.2. Inactivated
7.2.3. Live Attenuated
7.2.4. Toxoid
7.3. Market Analysis, Insights and Forecast – By Route of Administration
7.3.1. Parenteral
7.3.2. Oral
7.4. Market Analysis, Insights and Forecast – By Disease Indication
7.4.1. Viral Diseases
7.4.2. Bacterial Diseases
7.5. Market Analysis, Insights and Forecast – By Age Group
7.5.1. Pediatric
7.5.2. Adults
7.6. Market Analysis, Insights and Forecast – By Distribution Channel
7.6.1. Hospital & Retail Pharmacies
7.6.2. Government Suppliers
7.6.3. Others
7.7. Market Analysis, Insights and Forecast – By Country/Sub-region
7.7.1. U.K.
7.7.2. Germany
7.7.3. France
7.7.4. Spain
7.7.5. Italy
7.7.6. Scandinavia
7.7.7. Rest of Europe
8. Asia Pacific Vaccines Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Type
8.2.1. Recombinant/Conjugate/Subunit
8.2.2. Inactivated
8.2.3. Live Attenuated
8.2.4. Toxoid
8.3. Market Analysis, Insights and Forecast – By Route of Administration
8.3.1. Parenteral
8.3.2. Oral
8.4. Market Analysis, Insights and Forecast – By Disease Indication
8.4.1. Viral Diseases
8.4.2. Bacterial Diseases
8.5. Market Analysis, Insights and Forecast – By Age Group
8.5.1. Pediatric
8.5.2. Adults
8.6. Market Analysis, Insights and Forecast – By Distribution Channel
8.6.1. Hospital & Retail Pharmacies
8.6.2. Government Suppliers
8.6.3. Others
8.7. Market Analysis, Insights and Forecast – By Country/Sub-region
8.7.1. Japan
8.7.2. China
8.7.3. India
8.7.4. Australia
8.7.5. Southeast Asia
8.7.6. Rest of Asia Pacific
Continued...

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.